1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Opioid Use Disorder: Executive Summary
2.1 Reformulations of Buprenorphine Will Drive Growth in the OUD Market
2.2 Experienced and New Players Go Head-to-Head with Buprenorphine Reformulations
2.3 Environmental Unmet Needs of Greater Importance than Clinical Needs
2.4 Late-Stage Pipeline Remains Focused on Reformulations, While Early Stage Pipeline Looks to Novel MOAs
2.5 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of OUD
5.4.4 Forecast Assumptions and Methods: 12-Month Diagnosed Prevalent Cases of OUD
5.4.5 Forecast Assumptions and Methods: 12-Month Total and Diagnosed Prevalent Cases of OUD by Severity
5.4.6 Sources Not Used
5.5 Epidemiological Forecast for OUD (2018-2028)
5.5.1 12-Month Total Prevalent Cases of OUD
5.5.2 Age-Specific 12-month Total Prevalent Cases of OUD
5.5.3 Sex-Specific 12-Month Total Prevalent Cases of OUD
5.5.4 12-Month Total Prevalent Cases of OUD by Severity
5.5.5 12-Month Diagnosed Prevalent Cases of OUD
5.5.6 Age-Specific 12-Month Diagnosed Prevalent Cases of OUD
5.5.7 Sex-Specific 12-Month Diagnosed Prevalent Cases of OUD
5.5.8 12-month Diagnosed Prevalent Cases of OUD by Severity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6 Current Treatment Options
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Removal of Access Barriers
7.3 Novel Mechanisms of Action
7.4 Improved Treatment Guidelines

8 R&D Strategies
8.1 Overview
8.1.1 Drug Formulations That Have Less Potential for Abuse
8.1.2 Novel Mechanisms of Action
8.1.3 Extended-Release Formulations That Improve Compliance
8.2 Clinical Trials Design
8.2.1 Endpoints
8.2.2 Trial Duration
8.2.3 Comparator Arms
8.2.4 Patient Population

9 Pipeline Assessment
9.1 Overview
9.2 Innovative Early Stage Approaches
9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

11 Appendix

List of Tables
Table 1: Opioid Use Disorder: Key Metrics in the 8MM
Table 2: Symptoms of Opioid Use Disorder
Table 3: Long Term Psychological Impacts of Opioid Use Disorder
Table 4: DSM-5 Diagnostic Criteria for Opioid Use Disorder
Table 5: Risk Factors and Comorbidities for OUD
Table 6: Treatment Guidelines for Opioid Use Disorder
Table 7: Leading Treatments for Opioid Use Disorder, 2020
Table 8: Vaccines in Development for OUD, 2020
Table 9: Drugs in Development for Opioid Use Disorder, 2020
Table 10: Clinical Benchmark of Key Pipeline Drugs - OUD
Table 11: Commercial Benchmark of Key Pipeline Drugs - OUD
Table 12: Key Events Impacting OUD Sales, 2018-2028
Table 13: OUD Market - Global Drivers and Barriers, 2018-2028
Table 14: Key Historical and Projected Launch Dates for OUD
Table 15: Key Historical and Projected Patent Expiry Dates for OUD
Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for Opioid Use Disorder, 2018 and 2028
Figure 2: Competitive Assessment of the Pipeline Drugs Benchmarked Against the SOC, Suboxone
Figure 3: The Impact of Opioid Use Disorder on Brain Function
Figure 4: 8MM, 12-Month Total Prevalence of OUD, Men and Women, %, Ages ?18 Years, 2018
Figure 5: 8MM, 12-Month Diagnosed Prevalence of OUD, Men and Women, %, Ages ?18 Years, 2018
Figure 6: 8MM, Sources Used and Not Used to Forecast the 12-Month Total and 12-Month Diagnosed Prevalent Cases of OUD
Figure 7: 8MM, Sources Used to Forecast the Severity of 12-Month Total Prevalent Cases of OUD
Figure 8: 8MM, Sources Used to Forecast the Severity of 12-Month Diagnosed Prevalent Cases of OUD
Figure 9: 8MM, 12-Month Total Prevalent Cases of OUD, Both Sexes, Ages ?18 Years, N, 2018
Figure 10: 8MM, 12-Month Total Prevalent Cases of OUD by Age, N, Both Sexes, 2018
Figure 11: 8MM, 12-Month Total Prevalent Cases of OUD by Sex, N, Ages ?18 Years, 2018
Figure 12: 8MM 12-Month Total Prevalent Cases of OUD by Severity, N, Ages ?18 Years, 2018
Figure 13: 8MM, 12-Month Diagnosed Prevalent Cases of OUD, N, Both Sexes, Ages ?18 Years, 2018
Figure 14: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Age, N, Both Sexes, 2018
Figure 15: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Sex, N, Ages ?18 Years, 2018
Figure 16: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Severity, N, Ages ?18 Years, 2018
Figure 17: Unmet Needs and Opportunities in Opioid Use Disorder
Figure 18: Overview of the Development Pipeline in Opioid Use Disorder
Figure 19: Key Trials for the Promising Pipeline Agents Profiled by GlobalData in the Associated Excel File
Figure 20: Competitive Assessment of Pipeline Drugs Benchmarked Against the SOC, Suboxone
Figure 21: 8MM, OUD Sales Forecast by Country, 2018 and 2028
Figure 22: 8MM, OUD Sales Forecast by Class, 2018 and 2028
Figure 23: US OUD Sales Forecast by Class, 2018 and 2028
Figure 24: Canada OUD Sales Forecast by Class, 2018 and 2028
Figure 25: Europe OUD Sales Forecast by Country, 2018 and 2028
Figure 26: Europe OUD Sales Forecast by Class, 2018 and 2028
Figure 27: Australia OUD Sales Forecast by Class, 2018 and 2028

Companies Mentioned
- Alkermes
- Azanta
- BioDelivery Sciences International
- Braeburn
- Bristol-Myers Squibb
- Camarus
- Chiesi Pharmaceuticals
- DiaMo Narcotics
- Hikma Pharmaceuticals
- Indivior
- Knight Therapeutics
- MaynePharma Group
- MediciNova
- Molteni Farmaceutici
- Mundipharma
- Omeros Corp
- Orexo
- Reckitt Benckiser Group
- Sandoz
- Swissmedic
- Teva Pharmaceuticals
- Titan Pharmaceuticals